RT Journal Article
SR Electronic
T1 Observations from the OMERACT Drug Safety Summit, May 2008
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 2110
OP 2113
DO 10.3899/jrheum.090590
VO 36
IS 9
A1 LEE S. SIMON
A1 C. VIBEKE STRAND
A1 MAARTEN BOERS
A1 PETER M. BROOKS
A1 DAVID HENRY
A1 PETER S. TUGWELL
YR 2009
UL http://www.jrheum.org/content/36/9/2110.abstract
AB Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions.